MedPath

Substance Use Risk and Solution-Focused Approach

Not Applicable
Completed
Conditions
Self Efficacy
Registration Number
NCT06732206
Lead Sponsor
Ufuk DOĞAN
Brief Summary

Although substance abuse is the subject of serious struggles on the basis of individuals and countries, its rate of spread cannot be stopped and it creates an agenda with new people added every day. Substance addiction, which not only creates physiological problems in individuals, but also affects human health in every aspect with psychological and social problems, adversely affects the health status of individuals as well as their families and environments. The best way to get rid of addiction is to never start. Therefore, our study focused on preventing addiction, not addiction. After applying the Substance Use Tendency Scale and Self-Control Scale to university students, an intervention and control group will be formed. Solution Focused Approach program will be applied to the intervention group. At the end of the program, post-tests will be applied to the intervention and control groups.

Detailed Description

First of all, the Substance Use Tendency Scale (MDAS) and personal information form will be applied to the nursing students of the Faculty of Health Sciences, which consists of 750 people. A high score in any of the BCAS subscales indicates a tendency towards addiction. After this, students with a tendency will be determined. After the power analysis is performed, the appropriate number of samples will be determined. Finally, participants will be assigned to the intervention/control group by randomization. A substance use prevention psychoeducation program based on a solution-focused approach will be applied to the experimental group in 7 sessions for 6 weeks. No intervention will be made to the control group. At the end of psychoeducation, posttests will be collected from the experimental and control groups.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Changes in Students' Substance Use Risk Levels3 month period

The scale developed by Woicik et al. (2009) and showing good psychometric properties in non-clinical samples was validated and reliability-tested in Turkish by Uygun et al. (2019). It is a 23-item (4-point Likert scale: 1 strongly disagree, 4 strongly agree) measurement tool. The scale has four subdimensions: hopelessness/self-discontent, impulsivity, sensation seeking, and anxiety sensitivity. The Cronbach's alpha value is determined to be 0.728. If at least one of the subscale scores is found to be high, it indicates a high risk of substance use in the individua

"Changes in the Self-Control Levels of Students at Risk of Substance Use3 month period

The Self-Control Scale (SCS): The scale was developed by Rosenbaum in 1980. It measures how well individuals can use their existing control behaviors to solve problems they encounter in daily life. The Turkish validity and reliability studies were conducted by Duyan, Gülden, and Gelbal in 2012. The scale aims to estimate individuals' mental skills in controlling psychological and physiological responses such as anxiety, anger, and pain; delaying short-term satisfaction; initiating problem-solving processes; and self-efficacy perception. The scale consists of 3 sub-dimensions: Restorative Self-Control, Experiential Self-Control, and Renewing Self-Control, with a total of 36 items. Participants are asked to select one of the options prepared in a 6-point Likert type ranging from "Completely fits me +3" to "Completely does not fit me -3" in response to the questions. Higher scores on the scale indicate higher levels of self-control. The Cronbach's Alpha value was found to be 0.809.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Ufuk Doğan

🇹🇷

Elazığ, Turkey

Ufuk Doğan
🇹🇷Elazığ, Turkey

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.